Joint Clinical Trials Office

You are here

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Clinical Trial Details

This clinical trial is for men and women with unresectable locally-advanced or metastatic triple-negative breast cancer. There is currently a need for more effective treatment methods for this disease. 
    
The study drug that is being investigated in this clinical trial, SGN-LIV1A, is a type of drug called an antibody drug conjugate (ADC). Another study drug, Pembrolizumab, is a type of drug called a checkpoint inhibitor, or CPI. CPIs are antibodies that stick to and block a protein on cancer cells that helps them survive. This study is being done to test the safety and side effects of SGN-LIV1A and pembrolizumab when used together. 
    
You will be given SGN-LIV1A and pembrolizumab in 3-week cycles. If your cancer is stable or gets better, you may get up to 35 cycles with pembrolizumab. There is no set limit for how many cycles of SGN-LIV1A you can receive. After you have stopped getting these drugs, we will ask you to have follow up visits and/or follow-up phone calls every 3 months or until the study is closed. 

Key Eligibility: 
  • Open to men and women age 18 and older 
  • Diagnosed with unresectable locally-advanced or metastatic triple-negative breast cancer 
  • Detailed eligibility will be reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Marta Vallee Cobham, RN, BSN
(212) 821-0780
mac2034@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1711018791

ClinicalTrials.gov:

NCT03310957

Status

Open to Enrollment

Age Group

Adult

Sponsor